Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Fierce Biotech
BioVie plans $20M IPO for spinout developing liver disease drug
BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved low blood pressure drug to market.
James Waldron
Mar 17, 2026 5:18am
Gilead, Tokyo IPO, China's GLP-1 market—Fierce Pharma Asia
Feb 20, 2026 11:12am
Veradermics locks in $256M IPO, shares spike
Feb 5, 2026 10:01am
China biotech deals, Shionogi's ALS buy—Fierce Pharma Asia
Jan 9, 2026 3:00am
Enhertu, ADC trial deaths, Takeda—Fierce Pharma Asia
Dec 19, 2025 8:00am
Congress's biotech report, NIH ban, GSK-ABL—Fierce Pharma Asia
Apr 11, 2025 10:31am
